Development of a New Recurrence-Free Survival Prediction Nomogram for Patients with Primary Non-Muscle-Invasive Bladder Cancer Based on Preoperative Controlling Nutritional Status Score

References

• AntoniS, FerlayJ, SoerjomataramI, ZnaorA, JemalA, BrayF. Bladder cancer incidence and mortality: a global overview and recent trends. Eur Urol. 2017;71(1):96–108. Epub 2016 Jun 28. PMID: 27370177. doi:10.1016/j.eururo.2016.06.01027370177
   PubMed Web of Science ®Google Scholar
• JemalA, BrayF, CenterMM, FerlayJ, WardE, FormanD. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90. Epub 2011 Feb 4. Erratum in: CA Cancer J Clin. 2011 Mar-Apr;61(2):134. PMID: 21296855. doi:10.3322/caac.2010721296855
   PubMed Web of Science ®Google Scholar
• FerlayJ, ShinHR, BrayF, FormanD, MathersC, ParkinDM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893–2917. PMID: 21351269. doi:10.1002/ijc.2551621351269
   PubMed Web of Science ®Google Scholar
• BurgerM, CattoJW, DalbagniG, et al. Epidemiology and risk factors of urothelial bladder cancer. Eur Urol. 2013;63(2):234–241. Epub 2012 Jul 25. PMID: 22877502. doi:10.1016/j.eururo.2012.07.03322877502
   PubMed Web of Science ®Google Scholar
• KangM, JeongCW, KwakC, KimHH, KuJH. Preoperative neutrophil-lymphocyte ratio can significantly predict mortality outcomes in patients with non-muscle invasive bladder cancer undergoing transurethral resection of bladder tumor. Oncotarget. 2017;8(8):12891–12901. PMID: 28039452; PMCID: PMC5355064. doi:10.18632/oncotarget.1417928039452
   PubMedGoogle Scholar
• WangB, LiX, MingS, et al. Combined extraperitoneal and transperitoneal laparoscopic extended partial cystectomy for the treatment of urachal carcinoma. J Endourol. 2016;30(3):280–285. Epub 2015 Dec 18. PMID: 26531333. doi:10.1089/end.2015.042326531333
   PubMed Web of Science ®Google Scholar
• AlbayrakS, ZenginK, TanikS, et al. Can the neutrophil-to-lymphocyte ratio be used to predict recurrence and progression of non-muscle-invasive bladder cancer?Kaohsiung J Med Sci. 2016;32(6):327–333. Epub 2016 Jun 2. PMID: 27377847. doi:10.1016/j.kjms.2016.05.00127377847
   PubMed Web of Science ®Google Scholar
• HongSJ, ChoKS, HanM, et al; Korean Urological Oncology Society. Nomograms for prediction of disease recurrence in patients with primary Ta, T1 transitional cell carcinoma of the bladder. J Korean Med Sci. 2008;23(3):428–433. PMID: 18583878; PMCID: PMC2526537. doi:10.3346/jkms.2008.23.3.42818583878
   PubMed Web of Science ®Google Scholar
• BlackPC. Fine-tuning risk stratification for non-muscle-invasive bladder cancer. Eur Urol. 2016;69(1):70–71. PMID: 26256521. doi:10.1016/j.eururo.2015.07.03426256521
   PubMed Web of Science ®Google Scholar
• GuptaD, LisCG. Pretreatment serum albumin as a predictor of cancer survival: a systematic review of the epidemiological literature. Nutr J. 2010;9(1):69. PMID: 21176210; PMCID: PMC3019132. doi:10.1186/1475-2891-9-6921176210
   PubMed Web of Science ®Google Scholar
• HanahanD, WeinbergRA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–674. PMID: 21376230. doi:10.1016/j.cell.2011.02.01321376230
   PubMed Web of Science ®Google Scholar
• Ignacio de UlíbarriJ, González-MadroñoA, de VillarNG, et al. CONUT: a tool for controlling nutritional status. First validation in a hospital population. Nutr Hosp. 2005;20(1):38–45. PMID: 15762418.
   PubMedGoogle Scholar
• YoshidaN, BabaY, ShigakiH, et al. Preoperative nutritional assessment by Controlling Nutritional Status (CONUT) is useful to estimate postoperative morbidity after esophagectomy for esophageal cancer. World J Surg. 2016;40(8):1910–1917. PMID: 27220507. doi:10.1007/s00268-016-3549-327220507
   PubMed Web of Science ®Google Scholar
• SongH, XuB, LuoC, et al. The prognostic value of preoperative controlling nutritional status score in non-metastatic renal cell carcinoma treated with surgery: a retrospective single-institution study. Cancer Manag Res. 2019;11:7567–7575. PMID: 31496811; PMCID: PMC6693320. doi:10.2147/CMAR.S20941831496811
   PubMed Web of Science ®Google Scholar
• HiraharaN, TajimaY, FujiiY, et al. Controlling Nutritional Status (CONUT) as a prognostic immune nutritional biomarker for gastric cancer after curative gastrectomy: a propensity score-matched analysis. Surg Endosc. 2019;33(12):4143–4152. doi:10.1007/s00464-019-06723-z30838449
   PubMed Web of Science ®Google Scholar
• ZhangW, WuY, ZhangZ, et al. Controlling nutritional status score: a new prognostic indicator for patients with oligometastatic prostate cancer. Curr Probl Cancer. 2019;43(5):461–470. Epub 2019 Mar 15. PMID: 30910226. doi:10.1016/j.currproblcancer.2019.02.00130910226
   PubMed Web of Science ®Google Scholar
• TakagiK, BuettnerS, IjzermansJNM. Prognostic significance of the controlling nutritional status (CONUT) score in patients with colorectal cancer: a systematic review and meta-analysis. Int J Surg. 2020;78:91–96. Epub 2020 Apr 23. PMID: 32335238. doi:10.1016/j.ijsu.2020.04.04632335238
   PubMed Web of Science ®Google Scholar
• MontironiR, Lopez-BeltranA. The 2004 WHO classification of bladder tumors: a summary and commentary. Int J Surg Pathol. 2005;13(2):143–153. PMID: 15864376. doi:10.1177/10668969050130020315864376
   PubMed Web of Science ®Google Scholar
• PanerGP, StadlerWM, HanselDE, MontironiR, LinDW, AminMB. Updates in the eighth edition of the tumor-node-metastasis staging classification for urologic cancers. Eur Urol. 2018;73(4):560–569. Epub 2018 Jan 9. PMID: 29325693. doi:10.1016/j.eururo.2017.12.01829325693
   PubMed Web of Science ®Google Scholar
• SylvesterRJ, van der MeijdenAP, OosterlinckW, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006;49(3):466–5;discussion 475–7. Epub 2006 Jan 17. PMID: 16442208. doi:10.1016/j.eururo.2005.12.031
   PubMed Web of Science ®Google Scholar
• CumberbatchMGK, JubberI, BlackPC, et al. Epidemiology of bladder cancer: a systematic review and contemporary update of risk factors in 2018. Eur Urol. 2018;74(6):784–795. Epub 2018 Sep 26. PMID: 30268659. doi:10.1016/j.eururo.2018.09.00130268659
   PubMed Web of Science ®Google Scholar
• KluthLA, BlackPC, BochnerBH, et al. Prognostic and prediction tools in bladder cancer: a comprehensive review of the literature. Eur Urol. 2015;68(2):238–253. Epub 2015 Feb 21. PMID: 25709027. doi:10.1016/j.eururo.2015.01.03225709027
   PubMed Web of Science ®Google Scholar
• KimHS, KuJH, KimSJ, et al. Prognostic factors for recurrence and progression in Korean non-muscle-invasive bladder cancer patients: a Retrospective, Multi-Institutional Study. Yonsei Med J. 2016;57(4):855–864. PMID: 27189277; PMCID: PMC4951460. doi:10.3349/ymj.2016.57.4.85527189277
   PubMed Web of Science ®Google Scholar
• SfakianosJP, KimPH, HakimiAA, HerrHW. The effect of restaging transurethral resection on recurrence and progression rates in patients with nonmuscle invasive bladder cancer treated with intravesical bacillus Calmette-Guérin. J Urol. 2014;191(2):341–345. Epub 2013 Aug 20. PMID: 23973518; PMCID: PMC4157345. doi:10.1016/j.juro.2013.08.02223973518
   PubMed Web of Science ®Google Scholar
• PanCC, ChangYH, ChenKK, YuHJ, SunCH, HoDM. Constructing prognostic model incorporating the 2004 WHO/ISUP classification for patients with non-muscle-invasive urothelial tumours of the urinary bladder. J Clin Pathol. 2010;63(10):910–915. PMID: 20876324. doi:10.1136/jcp.2010.07976420876324
   PubMed Web of Science ®Google Scholar
• ShindoT, MasumoriN, KitamuraH, et al. Clinical significance of definite muscle layer in TUR specimen for evaluating progression rate in T1G3 bladder cancer: multicenter retrospective study by the Sapporo Medical University Urologic Oncology Consortium (SUOC). World J Urol. 2014;32(5):1281–1285. Epub 2013 Nov 5. PMID: 24190368. doi:10.1007/s00345-013-1205-124190368
   PubMed Web of Science ®Google Scholar
• Fernandez-GomezJ, MaderoR, SolsonaE, et al. Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model. J Urol. 2009;182(5):2195–2203. Epub 2009 Sep 16. PMID: 19758621. doi:10.1016/j.juro.2009.07.01619758621
   PubMed Web of Science ®Google Scholar
• DearnaleyD, SyndikusI, MossopH, et al; CHHiP Investigators. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, Phase 3 CHHiP trial. Lancet Oncol. 2016;17(8):1047–1060. Epub 2016 Jun 20. Erratum in: Lancet Oncol. 2016 Aug;17 (8): e321.PMID: 27339115; PMCID: PMC4961874. doi:10.1016/S1470-2045(16)30102-427339115
   PubMed Web of Science ®Google Scholar
• LiedbergF, HagbergO, HolmängS, et al. Local recurrence and progression of non-muscle-invasive bladder cancer in Sweden: a population-based follow-up study. Scand J Urol. 2015;49(4):290–295. Epub 2015 Jan 26. PMID: 25624049. doi:10.3109/21681805.2014.100096325624049
   PubMed Web of Science ®Google Scholar
• KılınçMF, BayarG, DalkılıçA, SönmezNC, ArısanS, GüneyS. Applicability of the EORTC risk tables to predict outcomes in non-muscle-invasive bladder cancer in Turkish patients. Turk J Urol. 2017;43(1):48–54. Epub 2017 Jan 6. PMID: 28270951; PMCID: PMC5330268. doi:10.5152/tud.2016.7760328270951
   PubMed Web of Science ®Google Scholar
• Busato JúniorWF, AlmeidaGL, RibasCA, Ribas FilhoJM, De CobelliO. EORTC risk model to predict progression in patients with non-muscle-invasive bladder cancer: is it safe to use in clinical practice?Clin Genitourin Cancer. 2016;14(2):176–182. Epub 2015 Sep 25. PMID: 26444918. doi:10.1016/j.clgc.2015.09.00526444918
   PubMed Web of Science ®Google Scholar
• CerboneL, SternbergCN, SengeløvL, et al. Results from a phase I Study of lapatinib with gemcitabine and cisplatin in advanced or metastatic bladder cancer: EORTC trial 30061. Oncology. 2016;90(1):21–28. Epub 2015 Oct 16. PMID: 26468947. doi:10.1159/00044095926468947
   PubMed Web of Science ®Google Scholar
• Ali AbdelhamidY, ChapmanMJ, DeaneAM. Peri-operative nutrition. Anaesthesia. 2016;71(Suppl 1):9–18. PMID: 26620142. doi:10.1111/anae.13310
   PubMed Web of Science ®Google Scholar
• LiuY, XueX. Systematic review of peri-operative nutritional support for patients undergoing hepatobiliary surgery. Hepatobiliary Surg Nutr. 2015;4(5):304–312. PMID: 26605277; PMCID: PMC4607833. doi:10.3978/j.issn.2304-3881.2014.12.0926605277
   PubMed Web of Science ®Google Scholar
• BallmerPE. Causes and mechanisms of hypoalbuminaemia. Clin Nutr. 2001;20(3):271–273. PMID: 11407876. doi:10.1054/clnu.2001.043911407876
   PubMed Web of Science ®Google Scholar
• PetersSJ, VanhaeckeT, PapeleuP, RogiersV, HaagsmanHP, van NorrenK. Co-culture of primary rat hepatocytes with rat liver epithelial cells enhances interleukin-6-induced acute-phase protein response. Cell Tissue Res. 2010;340(3):451–457. Epub 2010 Apr 22. PMID: 20411395; PMCID: PMC2882052. doi:10.1007/s00441-010-0955-y20411395
   PubMed Web of Science ®Google Scholar
• CohenS, DanzakiK, MacIverNJ. Nutritional effects on T-cell immunometabolism. Eur J Immunol. 2017;47(2):225–235. Epub 2017 Jan 24. PMID: 28054344; PMCID: PMC5342627. doi:10.1002/eji.20164642328054344
   PubMed Web of Science ®Google Scholar
• MellaM, KauppilaJH, KarihtalaP, et al. Tumor infiltrating CD8+ T lymphocyte count is independent of tumor TLR9 status in treatment naïve triple negative breast cancer and renal cell carcinoma. Oncoimmunology. 2015;4(6):e1002726. PMID: 26155410; PMCID: PMC4485740. doi:10.1080/2162402X.2014.100272626155410
   PubMed Web of Science ®Google Scholar
• KarantanosT, KaranikaS, SethB, GignacG. The absolute lymphocyte count can predict the overall survival of patients with non-small cell lung cancer on nivolumab: a clinical study. Clin Transl Oncol. 2019;21(2):206–212. Epub 2018 Jun 13. PMID: 29948974. doi:10.1007/s12094-018-1908-229948974
   PubMed Web of Science ®Google Scholar
• Vicente ConesaMA, Garcia-MartinezE, Gonzalez BillalabeitiaE, et al. Predictive value of peripheral blood lymphocyte count in breast cancer patients treated with primary chemotherapy. Breast. 2012;21(4):468–474. Epub 2011 Nov 26. PMID: 22119767. doi:10.1016/j.breast.2011.11.00222119767
   PubMed Web of Science ®Google Scholar
• HoskinPJ, RojasAM, PeirisSN, MullasseryV, ChongIY. Pre-treatment haemoglobin and peripheral blood lymphocyte count as independent predictors of outcome in carcinoma of cervix. Clin Oncol. 2014;26(4):179–184. Epub 2014 Jan 15. PMID: 24439272. doi:10.1016/j.clon.2013.11.023
   Web of Science ®Google Scholar
• WangC, LiP, XuanJ, et al. Cholesterol enhances colorectal cancer progression via ROS elevation and MAPK signaling pathway activation. Cell Physiol Biochem. 2017;42(2):729–742. Epub 2017 Jun 15. PMID: 28618417. doi:10.1159/00047789028618417
   PubMedGoogle Scholar
• StrasakAM, PfeifferRM, BrantLJ, et al; VHM&PP Study Group. Time-dependent association of total serum cholesterol and cancer incidence in a cohort of 172,210 men and women: a prospective 19-year follow-up study. Ann Oncol. 2009;20(6):1113–1120. Epub 2009 Jan 22. PMID: 19164459; PMCID: PMC2685450. doi:10.1093/annonc/mdn73619164459
   PubMed Web of Science ®Google Scholar
• HughesDA, TownsendPJ, HaslamPL. Enhancement of the antigen-presenting function of monocytes by cholesterol: possible relevance to inflammatory mechanisms in extrinsic allergic alveolitis and atherosclerosis. Clin Exp Immunol. 1992;87(2):279–286. PMID: 1370928; PMCID: PMC1554263. doi:10.1111/j.1365-2249.1992.tb02988.x1370928
   PubMed Web of Science ®Google Scholar
• GabitovaL, GorinA, AstsaturovI. Molecular pathways: sterols and receptor signaling in cancer. Clin Cancer Res. 2014;20(1):28–34. Epub 2013 Oct 24. PMID: 24158702; PMCID: PMC3859141. doi:10.1158/1078-0432.CCR-13-012224158702
   PubMed Web of Science ®Google Scholar
• CruzPM, MoH, McConathyWJ, SabnisN, LackoAG. The role of cholesterol metabolism and cholesterol transport in carcinogenesis: a review of scientific findings, relevant to future cancer therapeutics. Front Pharmacol. 2013;4:119. PMID: 24093019; PMCID: PMC3782849. doi:10.3389/fphar.2013.0011924093019
   PubMed Web of Science ®Google Scholar
• GadgilMD, AndersonCA, KandulaNR, KanayaAM. Dietary patterns are associated with metabolic risk factors in South Asians living in the United States. J Nutr. 2015;145(6):1211–1217. Epub 2015 Apr 22. PMID: 25904730; PMCID: PMC4442115. doi:10.3945/jn.114.20775325904730
   PubMed Web of Science ®Google Scholar
• ZhouP, LiB, LiuB, ChenT, XiaoJ. Prognostic role of serum total cholesterol and high-density lipoprotein cholesterol in cancer survivors: a systematic review and meta-analysis. Clin Chim Acta. 2018;477:94–104. Epub 2017 Dec 6. PMID: 29223765. doi:10.1016/j.cca.2017.11.03929223765
   PubMed Web of Science ®Google Scholar
• SakaiM, SohdaM, SaitoH, et al. Comparative analysis of immunoinflammatory and nutritional measures in surgically resected esophageal cancer: a Single-center Retrospective Study. In Vivo (Brooklyn). 2020;34(2):881–887. PMID: 32111799; PMCID: PMC7157860. doi:10.21873/invivo.11853
   Web of Science ®Google Scholar
• QiuX, SongY, CuiY, LiuY. Increased neutrophil-lymphocyte ratio independently predicts poor survival in non-metastatic triple-negative breast cancer patients. IUBMB Life. 2018;70(6):529–535. Epub 2018 Apr 29. PMID: 29707892. doi:10.1002/iub.174529707892
   PubMed Web of Science ®Google Scholar
• ZhuM, FengM, HeF, et al. Pretreatment neutrophil-lymphocyte and platelet-lymphocyte ratio predict clinical outcome and prognosis for cervical cancer. Clin Chim Acta. 2018;483:296–302. Epub 2018 May 22. PMID: 29758203. doi:10.1016/j.cca.2018.05.02529758203
   PubMed Web of Science ®Google Scholar
• ToyokawaT, KuboN, TamuraT, et al. The pretreatment Controlling Nutritional Status (CONUT) score is an independent prognostic factor in patients with resectable thoracic esophageal squamous cell carcinoma: results from a retrospective study. BMC Cancer. 2016;16(1):722. PMID: 27599460; PMCID: PMC5013653. doi:10.1186/s12885-016-2696-027599460
   PubMed Web of Science ®Google Scholar
• HiraharaN, MatsubaraT, HayashiH, TakaiK, NakadaS, TajimaY. Prognostic importance of controlling nutritional status in patients undergoing curative thoracoscopic esophagectomy for esophageal cancer. Am J Ther. 2018;25(5):e524–e532. PMID: 26866437; PMCID: PMC6133196. doi:10.1097/MJT.000000000000041426866437
   PubMed Web of Science ®Google Scholar
• HikageM, TaniyamaY, SakuraiT, et al. The influence of the perioperative nutritional status on the survival outcomes for esophageal cancer patients with neoadjuvant chemotherapy. Ann Surg Oncol. 2019;26(13):4744–4753. Epub 2019 Aug 22. PMID: 31440925. doi:10.1245/s10434-019-07742-931440925
   PubMed Web of Science ®Google Scholar
• TakagiK, BuettnerS, IjzermansJNM, WijnhovenBPL. Systematic Review on the Controlling Nutritional Status (CONUT) score in patients undergoing esophagectomy for esophageal cancer. Anticancer Res. 2020;40(10):5343–5349. PMID: 32988852. doi:10.21873/anticanres.1454132988852
   PubMed Web of Science ®Google Scholar
• IedaT, MutoS, ShimizuF, et al. Development and validation of a novel recurrence risk stratification for initial non-muscle invasive bladder cancer in Asia. EBioMedicine. 2016;12:98–104. Epub 2016 Sep 2. PMID: 27614395; PMCID: PMC5078579. doi:10.1016/j.ebiom.2016.08.05127614395
   PubMed Web of Science ®Google Scholar
• Ali-El-DeinB, SooriakumaranP, TrinhQD, BarakatTS, NabeehA. Construction of predictive models for recurrence and progression in >1000 patients with non-muscle-invasive bladder cancer (NMIBC) from a single centre. BJU Int. 2013;111(8):E331–E341. Epub 2013 Feb 27. PMID: 23445082. doi:10.1111/bju.1202623445082
   PubMed Web of Science ®Google Scholar